Maryland Senate Votes to Extend Psychedelics Task Force to 2027

Maryland's Senate voted unanimously this week to extend the state's psychedelics task force through December 2027, giving the panel additional time to develop recommendations on therapeutic access and potential regulatory frameworks for substances like psilocybin and MDMA.

The measure passed with full bipartisan support, reflecting growing legislative interest in psychedelic therapy following similar moves in Oregon, Colorado, and other states. The task force was originally set to sunset later this year.

"We need more time to get this right," said one Senate staffer familiar with the legislation, speaking on background. "The therapeutic potential is clear, but the regulatory questions are complex."

The bill moved through committee just days before the full Senate vote, advancing on the same day the House took up related psychedelics legislation. Maryland established its psychedelics task force in 2022 to study potential medical applications and recommend policy approaches. The group has met regularly but requested more time to complete its work.

What the Task Force Does

The panel includes medical professionals, law enforcement representatives, and patient advocates. Its mandate covers evaluating clinical research on substances like psilocybin, MDMA, and other psychedelics, along with examining regulatory models from other jurisdictions.

Maryland joins at least 15 other states that have created similar study groups or advisory bodies on psychedelics policy since 2020. Oregon became the first state to legalize supervised psilocybin therapy in 2020, with services launching in 2023. Colorado voters approved a comparable program in 2022.

The Maryland task force has already submitted preliminary findings to state lawmakers, but members say they need additional time to address questions about practitioner training, quality control standards, and equity in access to any future programs.

Industry Implications

The extension signals Maryland's continued interest in psychedelics policy, even as the state's cannabis market matures. Maryland launched adult-use cannabis sales in July 2023, and some industry observers see psychedelics as a natural next frontier.

"States that have established cannabis programs are often the first to take psychedelics seriously," said one policy analyst who tracks both industries. "They've already built the regulatory infrastructure and learned lessons about licensing and quality control."

But psychedelics present distinct challenges. Unlike cannabis, which patients can purchase and use independently, most proposed psychedelics frameworks require supervised sessions with trained facilitators. That creates different business models and regulatory needs.

What Happens Next

The bill now heads to the House, where it's expected to pass given the strong Senate support and parallel House interest in psychedelics policy. If signed into law, the task force would have nearly three more years to finalize its recommendations.

The extended timeline would allow the panel to observe how Oregon's and Colorado's programs develop, potentially incorporating lessons learned from those states' early implementation challenges. Oregon's program faced criticism for high costs and limited access in its first year.

Maryland lawmakers have until April 8 to pass legislation in the current session. The psychedelics task force extension is one of several drug policy bills under consideration, including measures related to cannabis expungement and medical marijuana patient protections.

The task force's next report to the legislature is due by December 2025, with a final set of recommendations expected before the 2027 sunset date.

This article is based on original reporting by www.marijuanamoment.net.